In a comparative study of over 1500 cases focusing on testing platforms and interpretation criteria in uterine serous carcinoma, the HER2 positivity rate varied from 10.5% to 19.6%, with the lowest number detected by NGS and the highest by FISH using the 2018 ASCO/CAP breast cancer guidelines [33]. This evidence concerns the gene ERBB2 and breast cancer.